Key TakeawaysThe FDA has granted Priority Review to Enhertu for the treatment of HER2-low and HER2-ultralow metastatic breast cancer, based on positive results...
Mantle Cell Lymphoma Treatment Advances with FDA Priority Review for Calquence
Key TakeawaysThe FDA has granted Priority Review for AstraZeneca's Calquence, a promising new treatment for untreated mantle cell lymphoma, based on data showing...
Enhertu Granted US Priority Review for HER2-Low Breast Cancer
Key TakeawaysEnhertu received Priority Review for HER2-low and HER2-ultralow metastatic breast cancer after endocrine therapy.
Phase 3 trial showed Enhertu improved progression-free survival...
Calquence Receives US Priority Review for Untreated Mantle Cell Lymphoma
Key TakeawaysCalquence granted Priority Review by the FDA for first-line treatment of mantle cell lymphoma (MCL).
Phase 3 trial data showed a 27%...
Cell Therapies Drive Innovation in Cancer Treatment Through Moffitt and AstraZeneca Collaboration
Key TakeawaysThe strategic collaboration between Moffitt Cancer Center and AstraZeneca aims to accelerate the development of innovative oncology cell therapies, including CAR T...
Datopotamab Deruxtecan Fails to Achieve OS Benefit in Breast Cancer Trial, But Shows PFS Gains
Key TakeawaysDatopotamab deruxtecan (Dato-DXd) did not reach statistical significance for overall survival (OS) in the TROPION-Breast01 Phase III trial.
The trial had previously...
Fasenra Receives EU CHMP Approval for EGPA
Key TakeawaysFasenra (benralizumab) recommended for EU approval as an add-on treatment for eosinophilic granulomatosis with polyangiitis (EGPA).
The approval is based on the...
Eosinophilic Granulomatosis with Polyangiitis: FDA Approves Fasenra for Treatment
Key TakeawaysThe FDA has approved AstraZeneca's Fasenra (benralizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), following successful results from the MANDARA...
Imfinzi Plus Imjudo: New Hope for Advanced Hepatocellular Carcinoma
Key TakeawaysAstraZeneca's Imfinzi plus Imjudo shows significant long-term survival in advanced liver cancer, with a 24% reduction in death risk.
Nearly 20% of...
Key HighlightsImfinzi perioperative regimen is the first immunotherapy before and after surgery to show statistically significant and clinically meaningful overall survival improvement in...
